Duritect™ tests to be launched following successful clinical validation
Highly accurate and non-invasive blood-based biomarker (BBM) tests for assessing the risk of Alzheimer's and Parkinson's diseases to be launched shortly following successful CLIA/CAP validation.
Durin appoints new Chief Strategy and Commercial Officer
Dennis Hutchison, JD, brings over 20 years of expertise in the diagnostics, lab tools, and pharmaceutical sectors.
.png)
Durin presents promising early results on its Duritect-AD test at AAIC 2024
Durin recently attended the Alzheimer's Association International Conference and presented its early results on its DuritectTM AD test which demonstrated one of the highest accuracies among Blood Based Biomarkers (BBMs) in the industry.
Durin receives additional funding to accelerate growth
The $3.5m funding, led by Breakthrough Diagnostics LLC, will accelerate our next key stages of anticipated growth – involving commercialization of our novel diagnostic tests.
Durin appoints new Chief Executive Officer
Dr. Mert Sahin is a highly accomplished business executive with an impressive track record of success in the life sciences sector.
Media Coverage: The Test - A Rowan professor’s mission to diagnose Alzheimer’s
Read more about this story on SJ Mag's website.
.png)
Media coverage: Researchers from Rowan and Durin announce highly accurate blood test for Alzheimer’s disease
Read more about this story on the Rowan University website.
Durin appoints new Chief Strategy and Commercial Officer
August 5, 2024
Durin presents promising early results on its Duritect-AD test at AAIC 2024
August 2, 2024